Targeted integration enables predictable clonal cell lines, enhancing transgene control and accelerating biopharma cell line development.
Hang Zhou
Advertisement
Hang Zhou, PhD, is head of Bioprocess Research & Development, WuXi Biologics.
Articles by Hang Zhou
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
2
Charles River Incubator Cohort to Accelerate CGT Development
3
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
4
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
5
